Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 37
- Registration Number
- NCT04615325
- Locations
- 🇺🇸
California Retina Consultants - Santa Maria, Santa Maria, California, United States
🇺🇸University Retina and Macula Associates, PC, Oak Forest, Illinois, United States
🇺🇸Austin Clinical Research LLC, Austin, Texas, United States
A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT04611776
A Study To Investigate The Safety, Tolerability And Pharmacokinetics (PK) Of RO7223280 Following Intravenous Administration In Healthy Participants
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 124
- Registration Number
- NCT04605718
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 220
- Registration Number
- NCT04603807
- Locations
- 🇩🇪
HELIOS Klinikum Emil von Behring Klinik f.Pneumologie Onkologie u.Infektiologie, Berlin, Germany
🇩🇪Kliniken Maria Hilf; Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach, Germany
🇮🇳Mahamana Pandit Madan Mohan Malaviya Cancer Centre-TMC, Varanasi, Uttar Pradesh, India
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 99
- Registration Number
- NCT04597918
- Locations
- 🇺🇸
Austin Research Center for Retina, Austin, Texas, United States
🇩🇪Universitätsklinikum Tübingen, Tübingen, Germany
🇮🇹Ospedale San Giuseppe; U.O. Oculistica, Milano, Lombardia, Italy
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 117
- Registration Number
- NCT04594707
- Locations
- 🇺🇸
Sarasota County Public Hospital, Sarasota, Florida, United States
🇺🇸NorthShore University HealthSystem, Evanston, Illinois, United States
🇺🇸Pulmonix Research, Greensboro, North Carolina, United States
A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 192
- Registration Number
- NCT04592341
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇵🇱Senior Sp. Z O.O. Poradnia Psychogeriatryczna, Sopot, Poland
🇫🇷Gerontopole; Centre de Recherche clinique, Toulouse, France
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 920
- Registration Number
- NCT04589845
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 746
- Registration Number
- NCT04586010
- Locations
- 🇺🇸
Johns Hopkins University School Of Medicine; Outpatient Center, Baltimore, Maryland, United States
🇺🇸OhioHealth, Columbus, Ohio, United States
🇺🇸The Boster Center for MS, Columbus, Ohio, United States
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 751
- Registration Number
- NCT04586023
- Locations
- 🇦🇹
Kepler Universitätskliniken GmbH - Med Campus III; Neurologie & Psychiatrie, Linz, Austria
🇦🇹Medizinische Universität Wien; Univ.Klinik fuer Neurologie, Wien, Austria
🇧🇷L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil